HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING—
Price Investing Group
← Back to Research Watchlist
RXRX
Recursion Pharmaceuticals Inc - Class A
Healthcare Biotechnology · Utah, USA · Reports in usd
—
Market Cap: $2.09B
Market Cap
$2.09B
Enterprise Val
$1.61B
P/E Ratio
-4.03
P/B Ratio
2.29
Trailing PEG (1Y)
0.10
As Of
Oct 7, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$915.0M
Gross Margin-49.82%
Profit Margin-49.82%
Return on Equity-50.41%
Return on Assets-38.25%
Current Ratio5.03
Debt/Equity0.07
LT Debt/Equity0.05
Revenue Per Share0.01

Income Statement

Jun 30, 2026
Revenue$7.7M
Cost of Revenue$11.5M
Gross Profit-$3.8M
R&D$89.6M
SG&A$41.5M
Operating Expenses$131.1M
Operating Income-$135.0M
Interest Expense$0.00
Tax Expense-$1.0K
Net Income-$131.0M
EPS (Basic)$-0.25
EPS (Diluted)$-0.25
EBIT-$131.0M
EBITDA-$107.6M
Consolidated Income-$131.0M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$551.1M
Accounts Receivable$14.4M
Inventory$0.00
Current Assets$603.5M
LT Investments$5.8M
Property, Plant & Equipment$147.1M
Intangibles$443.2M
Non-Current Assets$609.2M
Total Assets$1.21B
Accounts Payable$12.7M
Current Debt$22.7M
Current Liabilities$119.9M
LT Debt$43.9M
Non-Current Liabilities$177.8M
Total Liabilities$297.7M
Total Debt$66.6M
Retained Earnings-$2.32B
Shareholder Equity$915.0M
Shares Outstanding529,905,199

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$105.9M
Investing Cash Flow-$2.0M
Financing Cash Flow-$1.3M
CapEx-$44.0K
Free Cash Flow-$106.0M
Depreciation & Amort.$23.4M
Stock-Based Comp$19.5M
Acquisitions / Disposals$0.00
Investment Activity$0.00
Debt Issued/Repaid-$2.3M
Equity Issued/Repaid$984.0K
Dividends Paid$0.00
Net Change in Cash-$108.4M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h